Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 1.2× sales vs its 13.3× historical median P/S.
Fair value ≈ $0.00 · price $0.00 today
Undervalued · 91% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$NTRR 3 of 3
Great Q1 report. Revenue growth, profitability, positive cash flow, no dilution, and a reduction in outstanding shares are all steps in the right direction. Still work to do, but it’s good to see progress and execution from the NLS team. Looking forward to seeing what Q2 brings.
$NTRR 2 of 3
CASH Position
Cash increased from about $36,743 at January 31, 2026 to $49,910 at April 30, 2026. Operating activities generated positive cash flow of approximately $65,284.
Balance Sheet Concerns
The company still has:
Management specifically states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Neutra Life Sciences Continues to Drive the Story
The filing confirms that the clinical research subsidiary, Neutra Life Sciences (NLS), is now the primary growth engine. NLS operates clinical research sites across multiple specialties and generated the vast majority of Q1 revenue.
My Overall Assessment
For NTRR shareholders, this was probably the strongest quarterly filing in years because:
$NTRR 1 of 3
Quick overview: The Big Positive: Revenue Growth
Revenue jumped to $352,811 versus $68,057 in the same quarter last year — an increase of more than 400%. Most of the revenue came from the Neutra Life Sciences clinical research business, which generated approximately $325,811 during the quarter.
Profitability
The company reported a net profit of $84,505, compared to a loss of $109,023 in the prior-year quarter. This is a significant improvement and one of the strongest numbers shareholders have seen from NTRR.
No Dilution During the Quarter
Common shares outstanding remained at 2.917 billion shares, the same as the previous quarter. No new common stock was issued during Q1.
Share Cancellation
The company disclosed that 125 million shares were cancelled in February 2026 after a service agreement with Pacific Capital Markets was terminated.
$NTRR What a fkn crook Sydney is. Now he has diluted to the tune of 3.05 billion shares, and he has no way to pay those loans back other than trying to find another sucker to sell shares to so he will be diluting even further since he set it up so the authorized shares is "unlimited". The dude should be in prison.
$NTRR "driving sustainable growth and delivering meaningful results for our stakeholders".
What "growth" and "results" are you referring to? The results of shareholders losing all their money?
What a crock of BS. Sydney is a lying con man.
$NTRR CuraConnector on hold.
In addition, Neutra Corp. and CuraConnector.com have mutually agreed to defer any potential acquisition discussions and revisit the opportunity at a later time. This decision allows both parties to focus on their respective operational priorities while maintaining an open dialogue for future collaboration.
"Our priority right now is to build momentum within Neutra Life Sciences and scale our site management operations," said Sydney Jim. "By deferring acquisition talks, we ensure that our resources and attention are dedicated to driving sustainable growth and delivering meaningful results for our stakeholders."
